Raymond James & Associates’s Royalty Pharma RPRX Stock Holding History

Raymond James & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$22.8M	Buy	805,080 +71,402	+10%	+$1.98M	0.01%	747
2024 Q2	$19.3M	Sell	733,678 -50,871	-6%	-$1.41M	0.01%	796
2024 Q1	$23.8M	Buy	784,549 +560,897	+251%	+$16.5M	0.02%	694
2023 Q4	$6.28M	Buy	+223,652	New	+$6.15M	﹤0.01%	1383
2023 Q1	–	Sell	-7,240	Closed	-$286K	–	4042
2022 Q4	$286K	Sell	7,240 -7,388	-51%	-$308K	﹤0.01%	3246
2022 Q3	$588K	Buy	14,628 +2,680	+22%	+$114K	﹤0.01%	2754
2022 Q2	$502K	Buy	+11,948	New	+$490K	﹤0.01%	2913
2020 Q3	–	Sell	-4,223	Closed	-$205K	–	3677
2020 Q2	$205K	Buy	+4,223	New	+$209K	﹤0.01%	3122

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's RPRX Position: Q3 2024 in Review

Raymond James & Associates increased its Royalty Pharma (RPRX) stake by 9.7% in Q3 2024, buying an estimated $1.98M and bringing the position to 805,080 shares worth $22.8M. The position accounts for 0.01% of the portfolio, ranked #747.

Raymond James & Associates first reported a position in RPRX in Q2 2020 and has held it in 8 quarters since. The position peaked at $23.8M in Q1 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

Raymond James & Associates held 805,080 shares of Royalty Pharma worth $22.8M as of Q3 2024.
Raymond James & Associates bought 71,402 Royalty Pharma shares in Q3 2024, an estimated $1.98M.
Royalty Pharma made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #747 holding.
Raymond James & Associates first reported a position in Royalty Pharma in Q2 2020 and has held it in 8 quarters since.
Raymond James & Associates's Royalty Pharma position peaked at $23.8M in Q1 2024.
395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.